請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62689完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳信銘 | |
| dc.contributor.author | Nan-En Ho | en |
| dc.contributor.author | 何念恩 | zh_TW |
| dc.date.accessioned | 2021-06-16T16:07:33Z | - |
| dc.date.available | 2018-09-24 | |
| dc.date.copyright | 2013-09-24 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-06-07 | |
| dc.identifier.citation | 1. Jemal, A., F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman, Global cancer statistics. CA Cancer J Clin, 2011. 61(2): p. 69-90.
2. Cancer Registry Annual Report, 2008 Taiwan. Edited by 2010. 3. Warnakulasuriya, S., Global epidemiology of oral and oropharyngeal cancer. Oral Oncol, 2009. 45(4-5): p. 309-16. 4. van der Waal, I., Are we able to reduce the mortality and morbidity of oral cancer; some considerations. Med Oral Patol Oral Cir Bucal, 2013. 18(1): p. e33-7. 5. Sankaranarayanan, R., K. Ramadas, G. Thomas, R. Muwonge, S. Thara, B. Mathew, and B. Rajan, Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet, 2005. 365(9475): p. 1927-33. 6. Warnakulasuriya, S., N.W. Johnson, and I. van der Waal, Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med, 2007. 36(10): p. 575-80. 7. van der Waal, I., Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol, 2009. 45(4-5): p. 317-23. 8. Wang, Y.P., H.M. Chen, R.C. Kuo, C.H. Yu, A. Sun, B.Y. Liu, Y.S. Kuo, and C.P. Chiang, Oral verrucous hyperplasia: histologic classification, prognosis, and clinical implications. J Oral Pathol Med, 2009. 38(8): p. 651-6. 9. Hsue, S.S., W.C. Wang, C.H. Chen, C.C. Lin, Y.K. Chen, and L.M. Lin, Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital. J Oral Pathol Med, 2007. 36(1): p. 25-9. 10. Rajendran, R., Oral submucous fibrosis: etiology, pathogenesis, and future research. Bull World Health Organ, 1994. 72(6): p. 985-96. 11. Neville BW, Damn DD, Allen CM, Bouquot JE: Oral and maxillofacial pathology. Edited by John Dolan, Saunders Elsevier, 2009. 12. Shear, M. and J.J. Pindborg, Verrucous hyperplasia of the oral mucosa. Cancer, 1980. 46(8): p. 1855-62. 13. Reibel, J., Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med, 2003. 14(1): p. 47-62. 14. Petti, S., Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol, 2003. 39(8): p. 770-80. 15. Murti, P.R., R.B. Bhonsle, J.J. Pindborg, D.K. Daftary, P.C. Gupta, and F.S. Mehta, Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol, 1985. 13(6): p. 340-1. 16. Wong CY, C.H., Association between Predictors of Oral Potentially Malignant Disorders and Time to Malignant Transformation: a Cohort Study in Taiwan, in Graduate Institute of Clinical Dentistry School of Dentistry National Taiwan University Master Thesis2012, National taiwan university. p. 1-43. 17. Holmstrup, P., P. Vedtofte, J. Reibel, and K. Stoltze, Long-term treatment outcome of oral premalignant lesions. Oral Oncol, 2006. 42(5): p. 461-74. 18. Shi, P., W. Liu, Z.T. Zhou, Q.B. He, and W.W. Jiang, Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus. Cancer Epidemiol Biomarkers Prev, 2010. 19(3): p. 844-9. 19. Feng, J.Q., Z.Y. Xu, L.J. Shi, L. Wu, W. Liu, and Z.T. Zhou, Expression of cancer stem cell markers ALDH1 and Bmi1 in oral erythroplakia and the risk of oral cancer. J Oral Pathol Med, 2012. 20. Ma, L.W., Z.T. Zhou, Q.B. He, and W.W. Jiang, Phospholipase C-gamma1 expression correlated with cancer progression of potentially malignant oral lesions. J Oral Pathol Med, 2012. 21. Ma, L.W., Z.T. Zhou, Q.B. He, and W.W. Jiang, Phosphorylated p120-catenin expression has predictive value for oral cancer progression. J Clin Pathol, 2012. 65(4): p. 315-9. 22. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 144(5): p. 646-74. 23. Lodi, G., A. Sardella, C. Bez, F. Demarosi, and A. Carrassi, Interventions for treating oral leukoplakia. Cochrane Database Syst Rev, 2006(4): p. CD001829. 24. Lin, H.P., H.M. Chen, C.H. Yu, H. Yang, Y.P. Wang, and C.P. Chiang, Topical photodynamic therapy is very effective for oral verrucous hyperplasia and oral erythroleukoplakia. J Oral Pathol Med, 2010. 39(8): p. 624-30. 25. Yang, S.W., C.N. Tsai, Y.S. Lee, and T.A. Chen, Treatment outcome of dysplastic oral leukoplakia with carbon dioxide laser--emphasis on the factors affecting recurrence. J Oral Maxillofac Surg, 2011. 69(6): p. e78-87. 26. Jerjes, W., T. Upile, Z. Hamdoon, C.A. Mosse, S. Akram, and C. Hopper, Photodynamic therapy outcome for oral dysplasia. Lasers Surg Med, 2011. 43(3): p. 192-9. 27. Jerjes, W., T. Upile, Z. Hamdoon, M. Al-Khawalde, M. Morcos, C.A. Mosse, and C. Hopper, CO2 laser of oral dysplasia: clinicopathological features of recurrence and malignant transformation. Lasers Med Sci, 2012. 27(1): p. 169-79. 28. Nezis, I.P. and H. Stenmark, p62 at the interface of autophagy, oxidative stress signaling, and cancer. Antioxid Redox Signal, 2012. 17(5): p. 786-93. 29. Williams, J.A., A.M. Thomas, G. Li, B. Kong, L. Zhan, Y. Inaba, W. Xie, W.X. Ding, and G.L. Guo, Tissue specific induction of p62/Sqstm1 by farnesoid X receptor. PLoS One, 2012. 7(8): p. e43961. 30. Pankiv, S., T. Lamark, J.A. Bruun, A. Overvatn, G. Bjorkoy, and T. Johansen, Nucleocytoplasmic shuttling of p62/SQSTM1 and its role in recruitment of nuclear polyubiquitinated proteins to promyelocytic leukemia bodies. J Biol Chem, 2010. 285(8): p. 5941-53. 31. Moscat, J. and M.T. Diaz-Meco, p62 at the crossroads of autophagy, apoptosis, and cancer. Cell, 2009. 137(6): p. 1001-4. 32. Puls, A., S. Schmidt, F. Grawe, and S. Stabel, Interaction of protein kinase C zeta with ZIP, a novel protein kinase C-binding protein. Proc Natl Acad Sci U S A, 1997. 94(12): p. 6191-6. 33. Sanchez, P., G. De Carcer, I.V. Sandoval, J. Moscat, and M.T. Diaz-Meco, Localization of atypical protein kinase C isoforms into lysosome-targeted endosomes through interaction with p62. Mol Cell Biol, 1998. 18(5): p. 3069-80. 34. Moscat, J. and M.T. Diaz-Meco, p62: a versatile multitasker takes on cancer. Trends Biochem Sci, 2012. 37(6): p. 230-6. 35. Dolcet, X., D. Llobet, J. Pallares, and X. Matias-Guiu, NF-kB in development and progression of human cancer. Virchows Arch, 2005. 446(5): p. 475-82. 36. Karin, M., Y. Cao, F.R. Greten, and Z.W. Li, NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer, 2002. 2(4): p. 301-10. 37. Chen, H.Y. and E. White, Role of autophagy in cancer prevention. Cancer Prev Res (Phila), 2011. 4(7): p. 973-83. 38. Eskelinen, E.L., The dual role of autophagy in cancer. Curr Opin Pharmacol, 2011. 11(4): p. 294-300. 39. Kirkin, V. and I. Dikic, Ubiquitin networks in cancer. Curr Opin Genet Dev, 2011. 21(1): p. 21-8. 40. Ishii, T., K. Itoh, S. Takahashi, H. Sato, T. Yanagawa, Y. Katoh, S. Bannai, and M. Yamamoto, Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem, 2000. 275(21): p. 16023-9. 41. Inoue, D., T. Suzuki, Y. Mitsuishi, Y. Miki, S. Suzuki, S. Sugawara, M. Watanabe, A. Sakurada, C. Endo, A. Uruno, H. Sasano, T. Nakagawa, K. Satoh, N. Tanaka, H. Kubo, H. Motohashi, and M. Yamamoto, Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci, 2012. 103(4): p. 760-6. 42. Myung Park, J., S. Huang, T.T. Wu, N.R. Foster, and F.A. Sinicrope, Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther, 2012. 14(2). 43. Sansanwal, P. and M.M. Sarwal, p62/SQSTM1 prominently accumulates in renal proximal tubules in nephropathic cystinosis. Pediatr Nephrol, 2012. 27(11): p. 2137-44. 44. Rue, L., G. Lopez-Soop, E. Gelpi, M. Martinez-Vicente, J. Alberch, and E. Perez-Navarro, Brain region- and age-dependent dysregulation of p62 and NBR1 in a mouse model of Huntington's disease. Neurobiol Dis, 2013. 52: p. 219-28. 45. Pikkarainen, M., P. Hartikainen, and I. Alafuzoff, Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. J Neuropathol Exp Neurol, 2008. 67(4): p. 280-98. 46. Kuusisto, E., L. Parkkinen, and I. Alafuzoff, Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol, 2003. 62(12): p. 1241-53. 47. Williams, A.R., J. Piris, and A.H. Wyllie, Immunohistochemical demonstration of altered intracellular localization of the C-Myc oncogene product in human colorectal neoplasms. J Pathol, 1990. 160(4): p. 287-93. 48. Kitamura, H., T. Torigoe, H. Asanuma, S.I. Hisasue, K. Suzuki, T. Tsukamoto, M. Satoh, and N. Sato, Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue. Histopathology, 2006. 48(2): p. 157-61. 49. Choi, J., W. Jung, and J.S. Koo, Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Histopathology, 2013. 62(2): p. 275-86. 50. Clausen, T.H., T. Lamark, P. Isakson, K. Finley, K.B. Larsen, A. Brech, A. Overvatn, H. Stenmark, G. Bjorkoy, A. Simonsen, and T. Johansen, p62/SQSTM1 and ALFY interact to facilitate the formation of p62 bodies/ALIS and their degradation by autophagy. Autophagy, 2010. 6(3): p. 330-44. 51. Ishii, T., T. Yanagawa, K. Yuki, T. Kawane, H. Yoshida, and S. Bannai, Low micromolar levels of hydrogen peroxide and proteasome inhibitors induce the 60-kDa A170 stress protein in murine peritoneal macrophages. Biochem Biophys Res Commun, 1997. 232(1): p. 33-7. 52. Nagaoka, U., K. Kim, N.R. Jana, H. Doi, M. Maruyama, K. Mitsui, F. Oyama, and N. Nukina, Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. J Neurochem, 2004. 91(1): p. 57-68. 53. Mostowy, S., V. Sancho-Shimizu, M.A. Hamon, R. Simeone, R. Brosch, T. Johansen, and P. Cossart, p62 and NDP52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways. J Biol Chem, 2011. 286(30): p. 26987-95. 54. Jain, A., T. Lamark, E. Sjottem, K.B. Larsen, J.A. Awuh, A. Overvatn, M. McMahon, J.D. Hayes, and T. Johansen, p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem, 2010. 285(29): p. 22576-91. 55. Geetha, T., N. Vishwaprakash, M. Sycheva, and J.R. Babu, Sequestosome 1/p62: across diseases. Biomarkers, 2012. 17(2): p. 99-103. 56. Duran, A., J.F. Linares, A.S. Galvez, K. Wikenheiser, J.M. Flores, M.T. Diaz-Meco, and J. Moscat, The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell, 2008. 13(4): p. 343-54. 57. Inami, Y., S. Waguri, A. Sakamoto, T. Kouno, K. Nakada, O. Hino, S. Watanabe, J. Ando, M. Iwadate, M. Yamamoto, M.S. Lee, K. Tanaka, and M. Komatsu, Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol, 2011. 193(2): p. 275-84. 58. Stumptner, C., H. Heid, A. Fuchsbichler, H. Hauser, H.J. Mischinger, K. Zatloukal, and H. Denk, Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent. Am J Pathol, 1999. 154(6): p. 1701-10. 59. Jin, G.Z., Y. Li, W.M. Cong, H. Yu, H. Dong, H. Shu, X.H. Liu, G.Q. Yan, L. Zhang, Y. Zhang, X.N. Kang, K. Guo, Z.D. Wang, P.Y. Yang, and Y.K. Liu, iTRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma. J Proteome Res, 2011. 10(8): p. 3418-28. 60. Thompson, H.G., J.W. Harris, B.J. Wold, F. Lin, and J.P. Brody, p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene, 2003. 22(15): p. 2322-33. 61. Rolland, P., Z. Madjd, L. Durrant, I.O. Ellis, R. Layfield, and I. Spendlove, The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer, 2007. 14(1): p. 73-80. 62. Warnakulasuriya, S., T. Kovacevic, P. Madden, V.H. Coupland, M. Sperandio, E. Odell, and H. Moller, Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10-year period in South East England. J Oral Pathol Med, 2011. 40(9): p. 677-83. 63. Chiesa, F., P. Boracchi, N. Tradati, N. Rossi, L. Costa, R. Giardini, M. Marazza, and S. Zurrida, Risk of preneoplastic and neoplastic events in operated oral leukoplakias. Eur J Cancer B Oral Oncol, 1993. 29B(1): p. 23-8. 64. McCartan, B., Malignant transformation of leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1998. 85(4): p. 348-9. 65. Schoelch, M.L., N. Sekandari, J.A. Regezi, and S. Silverman, Jr., Laser management of oral leukoplakias: a follow-up study of 70 patients. Laryngoscope, 1999. 109(6): p. 949-53. 66. Vedtofte, P., P. Holmstrup, E. Hjorting-Hansen, and J.J. Pindborg, Surgical treatment of premalignant lesions of the oral mucosa. Int J Oral Maxillofac Surg, 1987. 16(6): p. 656-64. 67. Schepman, K.P., E.H. van der Meij, L.E. Smeele, and I. van der Waal, Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol, 1998. 34(4): p. 270-5. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62689 | - |
| dc.description.abstract | 背景
口腔癌前病變指的是有可能發展為口腔癌的病灶。然而由於缺乏預測其惡性轉變潛能的能力，直至目前為止對於口腔癌前病變的治療仍沒有共識。本實驗之目的在於找出能同時預測口腔癌前病變之惡性轉變潛能及口腔癌預後的因子。 實驗方法 本實驗蒐集57例在台大醫院經切片確診為口腔癌前病變並進一步發展成為口腔癌的病人。同時隨機選取63例切片確診為口腔癌前病變卻並未轉變成為口腔癌的病人做為對照。另外有20個正常黏膜組織及88例口腔癌的樣本一同研究。在這些組織中，我們使用免疫組織化學染色來試驗p62/SQSTM1的表現。病人的臨床及病理資料經整理後與p62的表現做比較。採用Kaplan-Meier graphs及Cox proportional hazard model進行存活分析。 結果 本實驗共蒐集了208例個案，包含20個正常的對照組，57個有轉變的口腔癌前病變，63個未轉變的口腔癌前病變及88例口腔癌。p62的表現形式在兩組口腔癌前病變的病人中有很大的不同。在具有較高p62細胞質表現或較低的細胞核表現的口腔癌前病變組織中，存在有較高的惡性轉變潛能及較短的惡性轉變時間。此外，p62的表現在口腔癌中顯著大於正常組織或口腔癌前病變。p62在細胞質的表現與腫瘤的大小，頸部淋巴轉移及腫瘤TNM分期相關(p值分別為0.042，0.032，0.009)。p62在細胞質中的高表現與口腔癌病人的5年存活率相關(p值為0.002)。經由Cox proportional hazard model，細胞質的p62表現之風險比為4.2(95%信頼區間為1.495-11.833)。 結論 p62/SQSTM1可作為預測口腔癌前病變之惡性轉變潛能的因子。細胞質中累積的p62及細胞核中沒有p62的表現顯示口腔癌前病變帶有較高的惡性轉變潛能。另一方面，p62在細胞質中的聚積也與口腔癌病人較差的預後相關。 | zh_TW |
| dc.description.abstract | Background
Oral potentially malignant disorders (OPMDs) were lesions that have a risk of transformation into oral cancer. Up to date, there is no any reliable method to predict malignant transformation of OPMD to be oral cancer, therefore, no consensus on how to treat OPMDs has been established. The aim of this study was to find a marker that can predict the malignant transformation potential of OPMDs and the prognosis of oral squamous cell carcinomas (OSCCs). Materials and methods The present study enrolled 57 patients with histology-proved OPMDs that further progress into OSCCs at National Taiwan University Hospital. We also recruited 63 patients with histology-proved OPMDs with no malignant transformation into oral cancer; 88 OSCC specimens as well as 20 normal mucosa tissues as the control groups. Immunohistochemical examination of p62/SQSTM1 was tested in these samples. The patients’ clinicopathological parameters were recorded and compared with their different expressions of p62. Kaplan-Meier graphs and Cox proportional hazard model were used for survival analysis. Results There were totally 208 patients enrolled in this study, including 20 normal controls, 57 progressing OPMDs, 63 non-progressing OPMDs, and 88 OSCCs. The expression pattern of p62 was significantly different between progress and non-progress OPMD groups. OPMDs with higher cytoplasmic p62 expression or lower nuclear immunoactivity exhibited greater malignant transformation potentiality and shorter transformation interval. Besides, the expression of p62 was highly discovered in oral cancer specimens than normal tissues or OPMDs. The cytoplasmic expression of p62 was related to tumor size (p=0.042), neck metastasis (p=0.032), and TNM stage (p=0.009). The high expression of p62 in cytoplasm also correlated with poor 5-year survival rate of OSCC patients (p=0.002). By Cox proportional hazard model, the hazard ratio of cytoplasmic p62 was 4.2 (95%CI, 1.495-11.833). Conclusion p62/SQSTM1 is a potential marker that can predict the malignant transformation of OPMDs. The accumulation of p62 expression in cytoplasm as well as negative expression in nucleus implies higher malignant transformation potentiality of OPMDs. In addition, p62 aggregates in cytoplasm is correlated with poor prognosis of OSCC patients. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T16:07:33Z (GMT). No. of bitstreams: 1 ntu-102-R00422028-1.pdf: 1098174 bytes, checksum: f5baadf2b1f0e522cef630a934c8b57a (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | CONTENTS
口試委員會審定書 # 誌謝 i CONTENTS ii LIST OF TABLES v LIST OF FIGURES vi 中文摘要 vii ABSTRACT ix Chapter 1 Introduction 1 1.1 The Epidemiology of Oral Cancer 1 1.2 Oral Potentially Malignant Disorders (OPMDs) 2 1.2.1 Terminology 2 1.2.2 Clinical Diagnosis of OPMDs 3 1.2.3 Pathological Diagnosis of OPMDs 5 1.2.4 Malignant Transformation of OPMDs 7 1.2.5 Treatment Modalities of OPMDs 10 1.3 p62/SQSTM1 11 1.3.1 The Structure and Function of p62/SQSTM1 11 1.3.2 The Role of p62/SQSTM1 in Different Cell Compartments 13 1.3.3 Induction of p62/SQSTM1 15 1.3.4 p62/SQSTM1 and Diseases 15 1.4 p62 and Cancers 16 1.4.1 p62 and Tumorigenesis 16 1.4.2 p62 and Tumor Survival 17 1.4.3 Expression of p62 in Human Cancers 18 1.5 Research Approach and Significance 20 Chapter 2 Materials and Methods 22 2.1 Selection of Subjects 22 2.1.1 Database of OPMDs 22 2.1.2 Case Selection 22 2.2 Specimen Preparation 23 2.3 Immunohistochemical Staining 24 2.4 Immunohistochemical Scoring 25 2.5 Statistical Analysis 25 Chapter 3 Results 26 3.1 Descriptive Demography 26 3.2 Immunohistochemical Results 27 3.3 Predictability of p62 for malignant transformation of OPMDs 29 3.4 Survival Analysis for Malignant Transformation of OPMDs 30 3.5 Survival Analysis for Overall Survival of OSCC 30 Chapter 4 Discussion 32 4.1 Principal Findings 32 4.2 Applications and future work 36 4.3 Limitations of this study 36 Chapter 5 Conclusions 38 Chapter 6 Figures and Tables 39 References 56 | |
| dc.language.iso | en | |
| dc.subject | 口腔癌 | zh_TW |
| dc.subject | p62/SQSTM1 | zh_TW |
| dc.subject | 口腔癌前病變 | zh_TW |
| dc.subject | 惡性轉變 | zh_TW |
| dc.subject | p62/SQSTM1 | en |
| dc.subject | oral potentially malignant disorders | en |
| dc.subject | oral squamous cell carcinoma | en |
| dc.subject | malignant transformation | en |
| dc.title | p62/SQSTM1作為口腔癌前病變惡性轉變之標記因子及口腔癌之預後因子之研究 | zh_TW |
| dc.title | The study of p62/SQSTM1 as a malignant transformation marker for oral potentially malignant disorders and a prognostic marker for oral squamous cell carcinoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 江俊斌,張龍昌 | |
| dc.subject.keyword | 口腔癌前病變,口腔癌,惡性轉變,p62/SQSTM1, | zh_TW |
| dc.subject.keyword | oral potentially malignant disorders,oral squamous cell carcinoma,malignant transformation,p62/SQSTM1, | en |
| dc.relation.page | 60 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2013-06-07 | |
| dc.contributor.author-college | 牙醫專業學院 | zh_TW |
| dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床牙醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 1.07 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。